Buprenorphine-naloxone (Suboxone)

Buprenorphine-naloxone (Suboxone) is a prescription medicine used to treat opioid use disorder. It pairs buprenorphine, a partial opioid agonist that eases withdrawal and cravings, with naloxone, an opioid blocker added to discourage misuse by injection. US labeling states it should be used inside a complete treatment plan that includes counseling and psychosocial support.

This page explains, in everyday language, what the medicine does, what the label warns about, how the film and tablet forms differ, and what a month realistically costs when you are paying yourself. It is a reference page, not a treatment plan, and not a place to obtain a prescription.

What buprenorphine-naloxone (Suboxone) is

Suboxone is a brand of sublingual film made by Indivior. The film dissolves under the tongue or against the inside of the cheek rather than being swallowed. Generic buprenorphine and naloxone films and dissolving tablets are also sold in the United States, and other brand names of the same combination exist.

It is a prescription-only medicine and a federally controlled substance in Schedule III. That classification shapes almost everything about access: how prescriptions are written, how many refills a clinician can give early in treatment, and which pharmacies keep it in stock.

People often ask whether buprenorphine is an opioid. It is. Buprenorphine is a partial opioid agonist, so it acts on the same receptors as heroin, oxycodone or fentanyl, just more weakly and for longer. Being an opioid is the point: it satisfies the receptor enough to stop withdrawal without producing the same rise and crash. Clinicians call this approach medication for opioid use disorder, and it is usually a long-term treatment rather than a short detox.

How buprenorphine and naloxone work together

Buprenorphine binds tightly to the mu opioid receptor but activates it only partly. Two things follow from that. First, it has a ceiling effect, so past a certain point more drug does not keep increasing sedation or breathing suppression the way a full agonist does. Second, because it holds on so tightly, it can block other opioids from attaching, which is why many people say a full dose of heroin or a pill feels muted or does nothing.

Naloxone is the ingredient that confuses people. Taken as directed under the tongue, very little naloxone reaches the bloodstream, so it does almost nothing. If the film or tablet is dissolved and injected, the naloxone becomes active and can trigger sharp withdrawal. It is a deterrent ingredient, and published work on buprenorphine misuse and diversion patterns is the reason the combination product became the default for take-home prescribing.

One practical consequence: the medicine has to sit in your mouth until it dissolves. Swallowing it too early wastes the dose. Patient-facing summaries from hospital systems, such as this guide to the buprenorphine and naloxone dissolving film, cover the mechanics of taking it correctly.

What it is approved to treat

The FDA-approved use is treatment of opioid dependence, now more commonly called opioid use disorder. The label is explicit that the medicine belongs inside a broader plan with counseling and psychosocial support, not on its own. In practice that support ranges from formal therapy to peer groups to regular check-ins, and programs differ a lot in how much they actually provide.

Combination buprenorphine and naloxone products are not approved for treating pain. Other buprenorphine formulations are approved for pain, which is a common source of confusion when people compare labels. If pain is part of your picture, that belongs in the conversation with your clinician rather than being solved by switching products yourself.

Research summarized by the National Institute on Drug Abuse on medications for opioid addiction links buprenorphine treatment with less illicit opioid use, better retention in care and lower risk of death. Those are population findings, not promises about any one person. Patient-education pages such as the NAMI overview of this combination medicine describe the same expectations in plain terms.

Starting it: precipitated withdrawal and the real three day rule

Because buprenorphine pushes other opioids off the receptor, starting it too soon after a full agonist can cause precipitated withdrawal: sudden, intense sickness that arrives within an hour instead of building slowly. That is the single most important thing to understand before the first dose.

The general shape of starting treatment usually looks like this:

1. A clinician takes a history: which opioids, how much, how recently, and what happened during past attempts.
2. You wait until clear withdrawal signs appear, on a timeline the clinician sets for the specific opioid involved.
3. The first dose is taken under the tongue, either in a clinic or at home with instructions and a way to reach someone.
4. The dose is adjusted over the following days until cravings and withdrawal settle.
5. You move into maintenance, with follow-up visits, refills and any counseling the program requires.

Fentanyl has made step two harder. It lingers in body tissue longer than older opioids, so the old waiting rules do not always apply, and clinicians now use different starting strategies. Do not improvise this from a forum post. Dosing and timing come from your prescriber and the official labeling, which you can look up through DailyMed, the NIH label database.

Searches for the Suboxone three day rule usually mean one of two different things. The federal version is a rule in the controlled substances regulations that lets a practitioner who is not running an opioid treatment program administer a narcotic to relieve acute withdrawal for up to three days while arranging ongoing care, one day at a time, and not as a prescription you take away. You can read the text of the 72 hour provision in federal regulation. The other meaning people intend is the waiting period before the first dose, which is a clinical judgment, not a fixed three days.

Side effects, from routine to rare

Most side effects reported on the label are the sort you would expect from an opioid, plus a few that come from holding a film in your mouth every day. Commonly reported effects include headache, nausea, vomiting, constipation, sweating, trouble sleeping, mouth numbness or soreness, redness inside the mouth, changes in taste and general aches. Withdrawal symptoms can also show up, particularly early on while the dose is being sorted out.

Some of this eases in the first weeks. Constipation often does not, and it is worth raising early rather than living with it.

Dental problems deserve their own mention. The FDA has warned about tooth decay and cavities with buprenorphine medicines dissolved in the mouth, including in people with no history of dental trouble. The recommended habit is to rinse your mouth gently with water once the dose has fully dissolved, swallow, and wait before brushing. Keeping up with a dentist matters more on this medicine, not less.

Less common but more serious problems include breathing that becomes slow or shallow, allergic reactions, liver injury, dizziness or fainting from low blood pressure when standing, and rarely adrenal problems that show up as ongoing fatigue, weakness and loss of appetite. Patient references such as the Mayo Clinic entry on sublingual buprenorphine and naloxone list these in more detail.

Warnings, interactions and who needs closer monitoring

The label carries several warnings that are worth understanding before you start, because a few of them change what else you can safely take.

• Breathing suppression: life threatening respiratory depression and deaths have happened with buprenorphine. The risk climbs sharply when it is combined with benzodiazepines, alcohol, sleep medicines, muscle relaxants, gabapentinoids or other central nervous system depressants.
• Misuse and diversion: buprenorphine can be misused like other opioids. That is why early treatment often means shorter prescriptions and more frequent contact rather than a long stack of refills.
• Accidental exposure in children: a single film or tablet can be fatal to a child. Keep doses in their original wrapper, out of sight and locked if possible, and dispose of unused medicine properly.
• Pregnancy and newborns: babies exposed before birth can have neonatal opioid withdrawal syndrome, which needs care after delivery. Stopping treatment is generally riskier than continuing, so this is a discussion to have with an obstetric clinician and a prescriber together, not a decision to make alone.
• Liver effects: hepatitis and other liver injury have been reported, so liver testing and monitoring may be part of care, especially with existing liver disease or hepatitis C.
• Interactions through liver enzymes: medicines that strongly inhibit or induce the CYP3A4 enzyme, including some antifungals, antibiotics, HIV medicines and seizure medicines, can change buprenorphine levels.
• Serotonin syndrome: combining with antidepressants, triptans or other serotonergic drugs carries a small risk of agitation, fever, fast heart rate and muscle rigidity.
• Opioid blockers: naltrexone and similar antagonists can cause withdrawal in someone on buprenorphine, so timing between the two matters.
• Do not stop abruptly: physical dependence is expected. Stopping suddenly can cause withdrawal, and tapering is a clinical decision.

The one absolute contraindication on the label is known hypersensitivity to buprenorphine or naloxone. Everything else is a matter of caution, monitoring and honest disclosure. Tell your prescriber about every substance you use, including alcohol, cannabis, benzodiazepines and anything bought outside a pharmacy. Withholding that information is what makes this medicine dangerous; disclosing it is what makes it safe.

It can also cause drowsiness and slowed reactions, particularly during the first weeks and after any change. Be careful with driving and machinery until you know how it affects you.

Films, tablets, generics and the other options

The choice between forms is usually about tolerance, cost and habit rather than one being clinically superior.

Film versus tablet

Films come in individual sealed wrappers and tend to dissolve reasonably quickly. Tablets are often cheaper, especially as generics, but some people find the grit or taste harder to tolerate. Both are placed in the mouth and left to dissolve. Neither should be chewed or swallowed whole.

Generic versus brand

FDA-approved generic buprenorphine and naloxone products must meet the agency’s bioequivalence standards, so a generic is not a lesser medicine. Taste, dissolving speed and inactive ingredients can differ, and price usually does. You can confirm which products are approved through the FDA’s Drugs@FDA database of approved products.

The buprenorphine only product

Buprenorphine without naloxone, historically sold as Subutex and now mostly generic, is sometimes used when the naloxone component is not wanted or not tolerated. Which product fits which situation is a clinical call, and guidance has shifted over the years.

Other medications for opioid use disorder

Comparing buprenorphine with naloxone against methadone is less about which drug is stronger and more about structure. One is a pharmacy prescription with periodic visits. The other is a program with daily attendance early on and tighter federal rules. Access, work schedules and transport often decide it. Other medicine explainers on the site sit in the medication reference index if you want to read across options.

Self-pay cost without insurance, and what moves it

There are two separate bills to keep straight, and merging them is how people end up surprised. One is the prescription itself, filled at a pharmacy. The other is the clinical program: the visit or membership fee that covers being assessed, prescribed to and followed up.

Across the telehealth programs tracked in the directory, the lowest recurring self-pay price a new patient can start on is a month, with a tracked median of a month. That figure is the program fee on the cash pay route, not the cost of the medicine at the counter, and advertised prices move, so treat any number as a starting point for your own check.

What pushes the total up or down:

• Brand versus generic: generic films and tablets are usually the cheaper line item at the pharmacy.
• Form and strength: different strengths and quantities price differently, and so does how many units a month covers.
• Pharmacy: cash prices for the same generic can vary between chains and independents in the same town.
• What the program fee includes: some fees cover unlimited messaging, counseling and lab work; others cover one short visit and charge for everything else.
• Intro versus renewal pricing: a low first month is not always the ongoing rate.
• Visit frequency: early treatment usually means more contact, so month one can cost more than month six.

To see what a monthly figure looks like over a year, and to compare paying cash against running it through a plan, these two calculators do the arithmetic:

Coverage, framed honestly

Buprenorphine products are among the more widely covered treatments in this category, and state Medicaid programs and commercial plans commonly include at least one option on formulary. That is context, not a promise. Formularies, prior authorization requirements, quantity limits and preferred products differ by plan and by state, and coverage policy tracking from KFF, which follows health coverage policy shows how much variation there is. Call the number on your card and ask about the specific product and strength before you assume anything. On this site, insurer pages such as the Medicare provider listings show which programs can bill a given plan, and the cash pay telehealth collection covers programs built around self-pay instead. Neither is a coverage guarantee, and copays and deductibles are separate from any fee shown.

If you want a worked example of how a month of treatment breaks down before you commit, the example savings report shows the format.

How telehealth programs prescribe it, and what varies

Prescribing has become less restricted than it once was. Federal law removed the separate waiver that clinicians previously needed for buprenorphine, so any prescriber with the appropriate DEA registration for Schedule III medicines can now prescribe it as part of normal practice. Telemedicine rules for controlled substances have been revised repeatedly, including provisions that have allowed remote evaluation for buprenorphine in defined circumstances, so confirm the current position with the program and with DEA Diversion Control, which publishes the prescribing rules rather than relying on an older article.

Between programs, the differences that actually affect your experience are these:

• States served: clinicians must be licensed where you are physically located, so coverage is patchy and changes.
• Induction support: whether someone is reachable on the day you take your first dose, and by what channel.
• Visit format: video, audio only, or a mix, and how long visits run.
• Counseling: included in the fee, offered as an add-on, or referred out entirely.
• Monitoring: how urine testing and any lab work are handled, and who pays.
• Refill rhythm: how often you are seen, how quickly a refill request is answered, and what happens on a weekend.
• Pharmacy handoff: because this is a controlled substance, it generally goes to a retail pharmacy rather than arriving by mail, and stock varies locally.
• Payment route: cash pay only, insurance billing, or both.

You can compare programs that treat opioid use disorder in the telehealth program directory, read how each dimension is weighted on the scoring methodology page, and browse longer pieces in the editorial archive. Other planning tools live in the free health calculators collection.

Questions to ask, and when to get help fast

Bring a short list to the first appointment. These tend to